Entries |
Document | Title | Date |
20080221212 | TOPICAL FORMULATION - There is described a topical formulation. The topical formulation includes: (i) diclofenac or a pharmaceutically acceptable salt thereof, (ii) a first compound, and (iii) a second compound. The first compound and second compound are different, and each is selected from the group consisting essentially of N-lauroyl sarcosine, sodium octyl sulfate, methyl laurate, isopropyl myristate, oleic acid, glyceryl oleate and sodium lauryl sulfoacetate. It has been discovered that certain combination of compounds are excellent penetration enhancers and, as such, can be incorporated in a topical formulation to facilitate administration of diclofenac or a pharmaceutically acceptable salt thereof. The increased penetration enhancement can also lead to a reduction in the total concentration of skin irritants in the formulation. | 09-11-2008 |
20080249176 | Methods and Compositions for the Treatment of Myocardial Conditions - The present invention relates to methods for the treatment of conditions characterised by abnormalities of myocardial cell ion levels, such as Na | 10-09-2008 |
20080249177 | AMINO ALCOHOL DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME, AND USE THEREOF - The present invention provides compounds represented by general formula (I): | 10-09-2008 |
20080255235 | Infusion and Injection Solution of Levodopa - An infusion or injection solution of Levodopa containing at least 10 mg/mL of Levodopa, or at least 5 mg/mL of Levodopa together with at least 0.5 mg/mL of at least one inhibitor of a Levodopa-metabolising enzyme is disclosed. The solution further contains a buffer, a physiologically acceptable sugar, such as glucose, a physiologically acceptable acid, such as hydrochloric acid, and optionally a stabilizer, and has a pH of lower than or equal to 6. There are also described a disposable syringe containing an infusion or injection solution of Levodopa, optionally together with a Levodopa-metabolising enzyme, and an infusion pump cassette containing an infusion or injection solution of Levodopa optionally together with a Levodopa-metabolising enzyme. | 10-16-2008 |
20080255236 | Methods and Composition Comprising 2-[(3-Chlorophenyl)Amino] Phenylacetic Acid for Alzheimer's Disease - The present invention is directed to a method of preventing or arresting the progression of Alzheimer's disease by administering to a patient having Alzheimer's disease a composition comprising an amount of 2-[(3-chlorophenyl)amino]phenylacetic acid, or a pharmaceutically acceptable salt thereof, sufficient to elicit a prophylactic or therapeutic effect. In some embodiments, the composition is administered orally, transdermally, intravenously, intrathecally, or by suppository. In some embodiments, the composition comprises a pharmaceutically acceptable carrier. | 10-16-2008 |
20080269333 | ANTHRANILIC ACID DERIVATIVES USEFUL IN TREATING INFECTION WITH HEPATITIS C VIRUS - The present invention provides pharmaceutical compositions useful in treating hepatitis C infection. The present invention also provides methods of treating hepatitis C infection by administering to a mammal the pharmaceutical compositions of the present invention. | 10-30-2008 |
20080287543 | Pharmaceutical composition comprising 5-methyl-2 (2'-chloro-6'-fluoroanillino) phen ylacetic acid - The invention relates to a composition for the treatment of a cyclooxygenase-2-mediated disorder or condition comprising 5-methyl-2-(2′-chloro-6′-fluoroanilino)phenylacetic acid or a pharmaceutically acceptable salt, preferably the potassium salt, thereof suitable for parenteral administration, and to a method for the treatment of a cyclooxygenase-2-mediated disorder or condition in a human or animal in need of such treatment by parenteral administration of 5-methyl-2-(2′-chloro-6′-fluroanilino)phenylacetic acid or a pharmaceutically acceptable salt, preferably the potassium salt, thereof. | 11-20-2008 |
20080293814 | CONCENTRATE ESMOLOL - A concentrate esmolol formulation is provided that is safer than current concentrate (e.g., 250 mg/ml) esmolol compositions. The concentrate esmolol formulation can include from about 40-60 mg/ml of esmolol hydrochloride. The concentrate esmolol composition allows a practitioner the flexibility of choosing a bolus volume for direct injection to a patient or, optionally, to use the composition to make a customized, diluted composition of esmolol. Methods of the present invention provide for the reduction of potential adverse health consequences resulting in the improper dosing of prior art concentrate compositions of esmolol. Also, a medical product is provided that includes a concentrate esmolol housed in a container, and a package housing the container and instructions. | 11-27-2008 |
20080300310 | Methods of administering diclofenac compositions for treating photodamaged skin, rosacea and/or acne - A method of treating at least one dermatological disorder selected from the group consisting of photodamage-induced wrinkles, rosacea, and acne, includes: (a) providing a composition containing 1-3 wt. % diclofenac or a salt thereof, 0.5-1.5 wt. % benzyl alcohol, 10-30 wt. % PEG monomethyl ether, 0.1-3.0 wt. % sodium hyaluronate; and 70-80 wt. % water; and (b) applying the composition to skin of a person in need of the treating in an amount effective to treat the at least one dermatological disorder. | 12-04-2008 |
20080300311 | DICLOFENAC GEL - The present invention provides a gel formulation comprising diclofenac sodium which has superior transdermal flux properties, which may be used for the topical treatment of pain, such as in osteoarthritis. | 12-04-2008 |
20080306160 | Preventive or therapeutic agent for disease caused by decrease in lacrimal fluid - The present invention provides pharmaceuticals for the prevention or treatment of diseases associated with decrease in tear. That is, the present invention provides pharmaceuticals for the prevention or treatment of diseases associated with decrease in tear such as dry eye, dry disorders of cornea and conjunctiva, disorders of the keratoconjunctival epithelium, syndrome with decrease in tear secretion, xerophthalmia, dry eye due to aging, opthalmopathy in Stevens-Johnson syndrome, opthalmopathy in Sjögren's syndrome, keratoconjunctival ulcer, dryness in wearing of contact lens or the like, which comprises a β | 12-11-2008 |
20090005451 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS - Agents useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis are disclosed. | 01-01-2009 |
20090012170 | TREATMENT OF SYMPTOMS OF MOTOR DYSFUNCTION - The present invention relates to the use of a COMT inhibitor in combination with a dopamine precursor and a peripheral decarboxylase inhibitor in the treatment of motor dysfunctions. | 01-08-2009 |
20090030082 | SYNTHETIC LIGANDS SELECTIVE FOR LXRbeta OVER LXRalpha, IDENTIFICATION AND METHODS OF USE THEREOF - LXR nuclear receptor agonists have been previously shown to increase cholesterol efflux, raise plasma HDL cholesterol, stimulate cholesterol excretion, and reduce atherosclerotic lesions. However, these agonists have also been associated with the unwanted side effect of hypertriglyeridemia. This hypertriglyeridemia appears to be mediated by the LXRα subtype rather than LXRβ, which suggests that LXRβ-selective agonists are attractive candidates for modulation of human lipid metabolism. The present application provides novel LXRβ-selective ligands that preferably modulate LXRβ over LXRα. These ligands may be used to treat a variety of diseases associated with LXR, such as for example lipid metabolism disorders, atherosclerosis, Alzheimer disease, and inflammation. | 01-29-2009 |
20090042989 | NSAID FORMULATIONS, BASED ON HIGHLY ADAPTABLE AGGREGATES, FOR IMPROVED TRANSPORT THROUGH BARRIERS AND TOPICAL DRUG DELIVERY - The invention describes novel formulations of nonsteroidal anti-inflammatory drugs (NSAIDS) based on complex aggregates with at least three amphipatic components suspended in a suitable, e.g. pharmaceutically acceptable, polar liquid medium. A suitably ionised NSAID is one of the two, amongst said three, components that tends to destabilise lipid membranes, the other system component with such activity being typically a surfactant. In contrast, the remaining amongst said at least three amphipatic components typically forms a stable lipid membrane on it's own. An essential characteristics of the resulting, relatively large, aggregates is an improved ability to penetrate pores, in a semi-permeable barrier, at least 30%, and often much smaller than the average diameter of the complex aggregate. This enables said aggregates to mediate NSAID transport through semi-permeable barriers including mammalian skin. As a result of the skin penetration by NSAID loaded large aggregates, the drug delivered transcutaneously with such carriers gets deeper into the tissue than the corresponding NSAID from a solution on the skin surface. This is believed to be due to the special ability of suitable large carriers to bypass the local sink of blood capillaries at the epidermal-dermal junction in the skin. The carrier-mediated delivery of locally applied NSAIDs thus allows therapy of deep tissues under the drug administration site, which is medically highly desirable. | 02-12-2009 |
20090048343 | Compounds and Their Salts Specific to the PPAR Receptors and the EGF Receptors and Their Use in the Medical Field - The present invention relates to compounds comprising the general formula (I), in which R | 02-19-2009 |
20090048344 | Pharmaceutical composition comprising 5-methyl-2-2' (chloro-6'-fluoroanilino phe nylacetic acid - Provided are compositions comprising aqueous suspensions of 5-methyl-2-(2′-chloro-6′-fluoroanilino)phenylacetic acid suitable for oral administration. Methods for making such compositions and methods for their stabilization are provided. | 02-19-2009 |
20090076150 | DEUTERIUM-ENRICHED BROMFENAC - The present application describes deuterium-enriched bromfenac, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 03-19-2009 |
20090076151 | METHOD FOR STIMULATING WEIGHT LOSS AND/OR FOR LOWERING TRIGLYCERIDES IN PATIENTS - Administration of a therapeutically effective amount of 3,5-diiodothyropropionic acid stimulates weight loss in patients, lowers triglyceride levels and reduces risk of death or progression of coronary heart disease in patients with metabolic syndrome. | 03-19-2009 |
20090082451 | USE OF THYROID HORMONE CONVERSION INHIBITORS - The present invention is directed to the use of thyroid hormone conversion inhibitors to treat hyperproliferative skin disorders, preferably their use in topical admixtures. | 03-26-2009 |
20090082452 | DEUTERIUM-ENRICHED LUMIRACOXIB - The present application describes deuterium-enriched lumiracoxib, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 03-26-2009 |
20090131527 | NOVEL ANTHRANILIC ACID DERIVATIVES AND CHLORIDE CHANNEL BLOCKING AGENT CONTAINING THE SAME - The present invention relates to novel anthranilic acid derivatives represented by Chemical Formula I, and a chloride channel blocking agent containing the anthranilic acid derivative or its pharmacologically acceptable salts as an active ingredient. In another aspect, the present invention relates to a method of accurately and efficiently detecting the intracellular chloride channel inhibition and method of screening a chloride channel blocking agent. | 05-21-2009 |
20090149542 | COMPOUNDS AND COMPOSITIONS FOR TREATING NEURONAL DEATH OR NEUROLOGICAL DYSFUNCTION - The present invention relates to 2-hydroxy-alkylamino-benzoic acid derivatives and to a combination of cell necrosis inhibitor and lithium, process for the preparation of the derivatives or the combination, pharmaceutical formulation containing the derivatives or the combination, and use of the derivatives or the combination by either concomitant or sequential administration for improvement of treatment of neuronal death or neurological dysfunction. The derivatives and the combination of the present invention are useful for treating neurological diseases, such as amyotrophic lateral sclerosis (ALS, Lou Gehrig's disease), spinal muscular atrophy, Alzheimer's disease, Parkinson's disease, Huntington's disease, stroke, traumatic brain injury or spinal cord injury; and for treating ocular diseases such as glaucoma, diabetic retinopathy or macular degeneration. | 06-11-2009 |
20090149543 | SOLID PHARMACEUTICAL COMPOSITIONS COMPRISING LUMIRACOXIB - A method of treating a cyclooxygenase-2 dependent disorder or condition comprising administering 5-methyl-2-(2′-chloro-6′-fluoroanilino)phenylacetic acid in an amount effective to treat such a disorder or condition for about 24 hours, comprising administering orally once a day to a human in need of such treatment one or more immediate release pharmaceutical compositions comprising 5-methyl-2-(2′-chloro-6′-fluoroanilino)phenylacetic acid, and compositions suitable for use in such methods. | 06-11-2009 |
20090163593 | AMINES THAT INHIBIT A MAMMALIAN ANANDAMIDE TRANSPORTER, AND METHODS OF USE THEREOF - One aspect of the present invention relates to amines. A second aspect of the present invention relates to the use of the amines as inhibitors of a mammalian anandamide transporter. The compounds of the present invention will also find use in the treatment of numerous ailments, conditions and diseases which afflict mammals, including but not limited to asthma, neuropathic pain, persistent pain, inflammatory pain, hyperactivity, hypertension, brain ischemia, Parkinson's disease, spasticity, Tourette's syndrome, schizophrenia, hemorrhagic shock, septic shock, cardiac shock, migrane, Horton's headache, multiple sclerosis, anorexia, AIDS wasting syndrome, organ rejection, autoimmune diseases, allergy, arthritis, Crohn's disease, malignant gliomas, neurodegenerative diseases, Huntington's chorea, glaucoma, nausea, anxiety, psychosis, attention deficit hyperactivity disorder, premature ejaculation, and stroke. Another aspect of the present invention relates to combinatorial libraries of amines, and methods for preparing the libraries. | 06-25-2009 |
20090170948 | Crystal forms of O-desmethylvenlafaxine fumarate - Provided are crystalline forms of O-desmethylvenlafaxine fumarate, methods for their preparation, and pharmaceutical compositions thereof. | 07-02-2009 |
20090197960 | Method of Inhibiting Polyneuropathic Pain with 3-(2-Dimethylaminomethylcyclohexyl) Phenol - A method of using 3-(2-dimethylaminomethylcyclohexyl)phenol or a pharmaceutically acceptable salt thereof as an active pharmaceutical ingredient for treating or inhibiting polyneuropathic pain, in particular in diabetic polyneuropathy. | 08-06-2009 |
20090197961 | Diclofenac Formulations and Methods of Use - Methods and formulations are provided for treating migraine and other acute pain episodes using diclofenac, and formulations of diclofenac that provide both rapid and sustained relief from acute pain. Methods and formulations are also provided for treating symptoms that often accompany migraine and acute pain such as photophobia, phonophobia, nausea and vomiting. | 08-06-2009 |
20090221707 | Process for preparing a pharmaceutical composition with anti-inflammatory and analgesic activity for administration via a patch for external use, and composition thus obtained - The present invention relates to a process for preparing a pharmaceutical composition with anti-inflammatory and analgesic activity for administration via a patch for external use, its components including as active principle a salt of diclofenac, 2[(2,6-dichlorophenyl)amino]benzene-acetic acid, with a cyclic organic base chosen from hydroxyethylpyrrolidine or hydroxyethylpiperidine characterized in that said active principle is added to a mixture of one or more of said components, in the form of a solution in water and propylene glycol in a ratio of about 1:1 parts by weight. | 09-03-2009 |
20090234012 | ADMINISTRATION OF DOPA PRECURSORS WITH SOURCES OF DOPA TO EFFECTUATE OPTIMAL CATECHOLAMINE NEUROTRANSMITTER OUTCOMES - A method of treating neurotransmitter dysfunction in a patient by optimizing catecholamine levels by administration of L-3,4-dihydroxyphenylalanine (L-Dopa or Dopa) precursors in combination with a source of L-Dopa. The dopa precursor is preferably administered in such quantities such that the amount of dopa from the dopa precursors does not fluctuate and affect outcomes in the synthesis of dopamine from dopa administration. The dopa precursor source is preferably tyrosine, but may alternatively be phenylalanine, N-acetyl-tyrosine, any active isomer thereof, or any other dopa precursor. The source of L-Dopa may include any natural or synthetic source, including, but not limited to, Mucuna pruriens. | 09-17-2009 |
20090247638 | PHARMACEUTICAL USE OF COX-2-INHIBITORS IN ANGIOGENESIS-MEDIATED OCULAR DISORDERS - The invention provides a method of treating an angiogenesis-mediated ocular disorder, e.g. ocular neovascularisation, retinal neovascularisation, including neovascularisation following injury or infection, retrolental fibroplasias, and neovascular glaucoma, age-related macular degeneration, diabetic retinopathy, pathologic myopia, ocular histoplasmosis, neovascular glaucoma, retinopathy of prematurity, the after effects of corneal transplantation, control of postsurgical ocular inflammation (e.g. after cataract surgery), cystoid macular edema (CME), herpes keratitis, in a subject in need of such treatment which comprises administering to the subject an effective amount of a COX-2 inhibitor of formula I | 10-01-2009 |
20090270506 | CRYSTALLINE STRUCTURE OF OXIDOSQUALENE SYNTHASE - The present invention relates to crystal forms of mammalian OSC and the crystal structure information obtained from them, to methods of preparing such crystal forms, and to their use for the identification and/or design of inhibitors of OSC activity. A further subject matter of the invention are methods for the identification and/or design of inhibitor compounds of OSC activity, the inhibitor compounds of OSC activity identified by these methods and their use in pharmaceutical compositions for the treatment and/or prevention of diseases which are associated with OSC comprising hypercholesterolemia, hyperlipemia, arteriosclerosis, vascular diseases, mycoses, parasite infections and gallstones, and/or treatment and/or prophylaxis of impaired glucose tolerance, diabetes, tumors and/or hyperproliferative disorders, preferably for the treatment and/or prophylaxis of hypercholesterolemia and/or hyperlipemia. | 10-29-2009 |
20090270507 | Concentrated Liquid Thyroid Hormone Composition - This invention is directed generally to a liquid pharmaceutical composition comprising at least one thyroid hormone (particularly a composition further comprising at least one cyclodextrin compound), a process for making such a composition and a method of using such a composition to treat a condition associated with impaired thyroid hormone function. | 10-29-2009 |
20090292022 | Method of Treating Post-Surgical Acute Pain - A method is provided for treating pain in patients recovering from post-surgical trauma by administering between about 13 to about 30 mg of diclofenac potassium in a liquid dispersible formulation over a period of at least 24 hours, wherein the daily total amount of diclofenac potassium administered is less than or equal to about 100 mg. The method is particularly useful in treating acute pain in bunionectomy patients. | 11-26-2009 |
20090292023 | Method of Treating Post-Surgical Acute Pain - A method is provided for treating pain in patients recovering from post-surgical trauma by administering between about 13 to about 30 mg of diclofenac potassium in a liquid dispersible formulation over a period of at least 24 hours, wherein the daily total amount of diclofenac potassium administered is less than or equal to about 100 mg. The method is particularly useful in treating acute pain in bunionectomy patients. | 11-26-2009 |
20090298944 | PHARMACEUTICAL COMPOSITION - The present invention relates to a pharmaceutical composition of practically water insoluble or low water soluble compounds containing catechol moiety by enhancing the solubility of such compounds using one or more alkalising agent and optionally adding one or more pharmaceutically acceptable excipient. The present invention also relates to a process for preparing such pharmaceutical composition | 12-03-2009 |
20090312424 | AROMATIC PRODRUGS OF PROPOFOL, COMPOSITIONS AND USES THEREOF - Prodrugs of propofol, methods of making prodrugs of propofol, pharmaceutical compositions of prodrugs of propofol and methods of using prodrugs of propofol and pharmaceutical compositions thereof to treat or prevent diseases or disorders such as migraine headache pain and post-chemotherapy or post-operative surgery nausea and vomiting are disclosed herein. | 12-17-2009 |
20090326072 | USE OF 2-(2-NITRO-4-TRIFLUOROMETHYLBENZOYL)-l,3- CYCLOHEXANEDIONE IN THE TREATMENT OF PARKINSON'S DISEASE - The present invention relates to, inter alia, the use of 2-(2-Nitro-4-Trifluoromethylbenzoyl)-1,3-Cyclohexanedione (compound 2) in the treatment of a neurodegenerative disease, such as Parkinson's disease. The invention also relates to the use of the compound depicted as compound 2 or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the treatment of a neurodegenerative disease such as Parkinson's disease. | 12-31-2009 |
20100016436 | Transdermal Administration of Active Agents, in Particular Diclofenac - The present invention relates to compositions for transdermal administration of therapeutic agents for providing a local and sustained therapeutic effect, wherein the extent of systemic administration can be controlled. In particular, the invention relates to spreadable compositions, or compositions which may be solid at a temperature of about 25° C. or less and have a softening point of not higher than 35° C., for use in the treatment of pain and/or inflammation or administration of a local anaesthetic, wherein transdermal administration of the therapeutic agent may be either rapid or sustained. | 01-21-2010 |
20100016437 | ALPHA-AMINOAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF COGNITIVE DISORDERS - The present invention is in the field of pharmacotherapy of cognitive deficits in learning and memory by administering an α-aminoamide, particularly safinamide. Examples of disturbances in cognition that can be treated with compounds of the invention are the ones associated with disorders such as autism, dyslexia, attention deficit hyperactivity disorder, schizophrenia, obsessive compulsive disorders, psychosis, bipolar disorders, depression, Tourette's syndrome, Mild Cognitive Impairment (MCI) and disorders of learning in children, adolescents and adults, Age Associated Memory Impairment, Age Associated Cognitive Decline, Alzheimer's Disease, Parkinson's Disease, Down's Syndrome, traumatic brain injury Huntington's Disease, Progressive Supranuclear Palsy (PSP), HIV, stroke, vascular diseases, Pick's or Creutzfeldt-Jacob diseases, multiple sclerosis (MS), other white matter disorders and drug-induced cognitive worsening. | 01-21-2010 |
20100029769 | TOPICAL FORMULATION - There is described a topical formulation. The topical formulation comprises: (i) diclofenac or a pharmaceutically acceptable salt thereof, (ii) a first compound, and (iii) a second compound. The first compound and second compound are different, and each is selected from the group consisting essentially of N-lauroyl sarcosine, sodium octyl sulfate, methyl laurate, isopropyl myristate, oleic acid, glyceryl oleate and sodium lauryl sulfoacetate. It has been discovered that certain combination of compounds are excellent penetration enhancers and, as such, can be incorporated in a topical formulation to facilitate administration of diclofenac or a pharmaceutically acceptable salt thereof. The increased penetration enhancement can also lead to a reduction in the total concentration of skin irritants in the formulation. | 02-04-2010 |
20100029770 | Methods of treating mental retardation, down's syndrome, fragile X syndrome and autism - Subjects having at least one condition selected from the group consisting of mental retardation, Down's syndrome, fragile X syndrome and autism are treated with a composition that includes gamma-aminobutyric acid agonists and/or M1 muscarinic receptor antagonists. The gamma-aminobutyric acid agonist (GABA) can be a GABA(B) agonist, such as baclofen. GABA(B) agonists can be used in combination with Group I mGluR antagonists and M1 muscarinic receptor antagonists in methods of treating humans. | 02-04-2010 |
20100035993 | METHODS AND COMPOSITIONS COMPRISING 2-[(3-CHLOROPHENYL) AMINO] PHENYLACETIC ACID FOR HYPERPERMEABILITY AND NEOVASCULARIZATION DISORDERS OF THE RETINA - Method of preventing or arresting the progression of hyperpermeability and neovascularization of the retina by administering to a patient at risk for retinal microvascular disease a composition comprising a compound or pharmaceutically acceptable salt thereof that lowers the ocular ratio of VEGF to PEDF. | 02-11-2010 |
20100069493 | AQUEOUS PHARMACEUTICAL FORMULATION OF 4-[((4-CARBOXYBUTYL)-AMINO)METHYL]BENZOIC ACID - The present invention relates to an aqueous pharmaceutical formulation which comprises 4-[((4-carboxybutyl)-{2-[(4-phenethylbenzyl)oxy]phenethyl}amino)methyl]benzoic acid or a salt thereof. The present invention relates in particular to an aqueous pharmaceutical formulation which comprises 4-[((4-carboxybutyl)-{2-[(4-phenethylbenzyl)oxy]phenethyl}amino)methyl]benzoic acid and 2-amino-2-(hydroxymethyl)-1,3-propanediol (trometamol). | 03-18-2010 |
20100069494 | LOWERING OF PROTEINS ASSOCIATED WITH ALZHEIMER'S DISEASE BY INTERRUPTING GENE TRANSCRIPTION WITH A SMALL MOLECULE - A method of treating Alzheimer's disease in a patient. The method includes administrating tolfenamic acid to the patient to modulate precursors of pothgene intermediates. The treatment also lowers SP1, APP and Aβ1 levels. | 03-18-2010 |
20100087536 | AMINO ACID DERIVED PRODRUGS OF PROPOFOL, COMPOSITIONS, USES AND CRYSTALLINE FORMS THEREOF - The present invention provides a prodrug of propofol and crystalline forms thereof, methods of making the propofol prodrug and crystalline forms thereof, pharmaceutical compositions of the propofol prodrug and crystalline forms thereof, methods of using the propofol prodrug and crystalline forms thereof and pharmaceutical compositions thereof to treat diseases or disorders such as headache pain, post-chemotherapy or post-operative surgery nausea and vomiting, neurodegenerative disorders, and mood disorders. | 04-08-2010 |
20100087537 | REDUCED IRRITANT ENEMA FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE (IBD) - The present invention comprises packaged enemas for the treatment of Inflammatory Bowel Disease (IBD), having substantially pure 5-ASA as the active ingredient, with a liquid carrier medium having a material avoidance of bowel irritant substances, such as anti-oxidants for the 5-ASA active ingredient, including such sulfites as potassium metabisulfite, for example, and contained within a sealed and substantially oxygen-free barrier package, which may preferably be formed of a foil/polymer laminate, and which package contains or otherwise includes an oxygen scavenger, such as a an oxygen scavenging sachet. | 04-08-2010 |
20100099766 | Topical NSAID compositions having sensate component - Topical analgesic compositions comprising a topically administrable NSAID, a sensate agent and optionally a self-warming system, when administered to a patient in need thereof, provide significant improvements in the rate and extent of skin absorption, as well as impart a sensation of rapid and complete relief from pain. | 04-22-2010 |
20100099767 | Topical Pharmaceutical Formulation - A composition for topical application of an NSAID comprises a solution or suspension of the NSAID in a carrier system comprising a polyhydric alcohol, a glycol ether and an ester of A higher fatty acid, the carrier system being present as a single phase at ambient temperatures. The NSAID may be diclofenac as diclofenac acid. The polyhydric alcohol may be a glycol such as isopropylene glycol and the glycol ether may be a diethylene glycol ether such as diethylene glycol monoethyl ether. | 04-22-2010 |
20100120918 | NOVEL NON-AQUEOUS TOPICAL SOLUTION OF DICLOFENAC AND PROCESS FOR PREPARING THE SAME - A non-aqueous topical solution composition of pharmaceutically acceptable salt of diclofenac is disclosed. The non-aqueous topical solution composition comprises therapeutically effective amount of pharmaceutically acceptable salt of diclofenac, solublizer, penetration enhancer and solvent, and optionally a humectant, counter irritant, additional penetration enhancer and anti-oxidants and a process for preparing the same. | 05-13-2010 |
20100130612 | COMPOSITION CONTAINING CHITOSAN FOR SUSTAINED DRUG RELEASE - The present invention relates to a composition for sustained drug release, comprising chitosan dissolved in a solvent having a pH of below about 4.0, wherein the chitosan is selected from the group of chitosans precipitating in a pH range of between about 3.0 and about 7.5; and at least one drug compound soluble in the above chitosan solution. | 05-27-2010 |
20100144882 | Method of Treating Post-Surgical Acute Pain - A method is provided for treating pain in patients recovering from post-surgical trauma by administering between about 13 to about 30 mg of diclofenac potassium in a liquid dispersible formulation over a period of at least 24 hours, wherein the daily total amount of diclofenac potassium administered is less than or equal to about 100 mg. The method is particularly useful in treating acute pain in bunionectomy patients. | 06-10-2010 |
20100160437 | TOPICAL COMPOSITION COMPRISING A CYCLOFRUCTAN, A CARRIER AND A DRUG - The present invention relates in particular to a drug delivery system comprising a cyclofructan, a drug and a polymeric carrier. | 06-24-2010 |
20100168239 | Use of Rasagiline for the Treatment of Multiple System Atrophy - Disclosed is a method for the treatment of Multiple System Atrophy comprising administering to a subject an amount of R(+)-N-propargyl-1-aminoindan or a pharmaceutically acceptable salt thereof. | 07-01-2010 |
20100190859 | Citrate Salt of Rasagiline - The subject invention provides rasagiline citrate, its compositions and processes for the manufacture thereof. | 07-29-2010 |
20100197788 | Preventive or therapeutic agent for disease caused by decrease in lacrimal fluid - The present invention provides pharmaceuticals for the prevention or treatment of diseases associated with decrease in tear. That is, the present invention provides pharmaceuticals for the prevention or treatment of diseases associated with decrease in tear such as dry eye, dry disorders of cornea and conjunctiva, disorders of the keratoconjunctival epithelium, syndrome with decrease in tear secretion, xerophthalmia, dry eye due to aging, opthalmopathy in Stevens-Johnson syndrome, opthalmopathy in Sjögren's syndrome, keratoconjunctival ulcer, dryness in wearing of contact lens or the like, which comprises a β | 08-05-2010 |
20100197789 | ANTI-OBESITY AGENT AND USE THEREOF - Disclosed is a novel anti-obesity agent. Also disclosed is a therapeutic method using the anti-obesity agent. The anti-obesity agent comprises a GABA | 08-05-2010 |
20100197790 | CONTAINER FOR PHARMACEUTICAL USE FOR THE QUANTITATIVE RELEASE OF A SINGLE DOSE FOR ORAL ADMINISTRATION OF T3 AND T4 THYROID HORMONES IN SOLUTION - The present disclosure relates to a container for pharmaceutical use for the quantitative release of a single-dose for oral administration of the T3 and T4 thyroid hormones in solution, characterized by the fact of being formed with a plastic material having a Young's modulus between 10 and 80 MPa. | 08-05-2010 |
20100197791 | PHARMACEUTICALS FOR TRANSDERMAL USE ON ANIMALS - The invention relates to pharmaceutical preparations for use on animals, which are applied to the fur or the skin of the animal and whose active ingredient subsequently undergoes transdermal absorption. | 08-05-2010 |
20100204330 | Diclofenac Formulations and Methods of Use - Methods and formulations are provided for treating migraine and other acute pain episodes using diclofenac, and formulations of diclofenac that provide both rapid and sustained relief from acute pain. Methods and formulations are also provided for treating symptoms that often accompany migraine and acute pain such as photophobia, phonophobia, nausea and vomiting. | 08-12-2010 |
20100216887 | INTRATHECAL BACLOFEN PHARMACEUTICAL DOSAGE FORMS WITH FEWER DEGRADATION PRODUCTS - The present invention relates generally to a sterile, particulate-free, stable intrathecal baclofen solution with less than 0.5% 4-(4-chlorophenyl)-2-pyrrolidone, a degradation product. These solutions are stable under a variety of storage conditions and for extended periods of time. Also disclosed are methods for preparing such compositions. | 08-26-2010 |
20100222430 | Method of Treating Post-Surgical Acute Pain - A method is provided for treating pain in patients recovering from post-surgical trauma by administering between about 13 to about 30 mg of diclofenac potassium in a liquid dispersible formulation over a period of at least 24 hours, wherein the daily total amount of diclofenac potassium administered is less than or equal to about 100 mg. The method is particularly useful in treating acute pain in bunionectomy patients. | 09-02-2010 |
20100227927 | SALTS OF TRAMADOL AND NAPROXEN AND THEIR CRYSTAL FORMS IN THE TREATMENT OF PAIN - The present invention concerns salts of Tramadol and Naproxen and their crystalline forms, and compositions thereof, for the treatment of pain, as well as their process for preparation. | 09-09-2010 |
20100234462 | TOPICAL COMPOSITION - The invention relates to beneficial topical pharmaceutical compositions comprising diclofenac sodium salt in unusually low amounts. The compositions represent opaque emulsion-gels, in which diclofenac is kept fully dissolved. | 09-16-2010 |
20100240757 | SYSTEMS AND METHODS FOR DELIVERING A FLUID DRUG - Devices and methods for distributing a fluid, e.g., a fluid drug, are disclosed. Fluid-drug distribution can be advantageously utilized to help patients suffering from a disorder that affect fine motor skill usage, e.g., Parkinson's Disease. Some aspects are directed to dosing containers that are adapted to distribute one or more selected dosages of fluid from the container. In some instances, the containers are adapted to be operable by patients with hindered fingertip motor control to help dispense a fluid-drug, such as a fluid including carbidopa and levodopa. Other aspects are directed to a kit for distributing a fluid drug that can be stored with a longer shelf life in solid form. Also discussed herein are methods for distributing a fluid drug for treating a disorder such as Parkinson's Disease. | 09-23-2010 |
20100249233 | COMPOUND AND USE THEREOF IN THE TREATMENT OF AMYLOIDOSIS - The present invention relates to compounds of formula (I) for stabilizing the tetrameric form of transthyretin, compounds for use in the treatment or prevention of amyloidosis, and agents and medicaments comprising such compounds. | 09-30-2010 |
20100286276 | Substituted 1,3-Diphenylpropane Derivatives, Preparations and Uses Thereof - The present invention concerns substituted 1,3-diphenylpropane derivatives, pharmaceutical compositions comprising them and the therapeutic uses thereof, particularly in the field of human and animal health. | 11-11-2010 |
20100298438 | GENE EXPRESSION PROFILING OF PARKINSON'S DISEASE - The present invention identifies the changes in gene expression associated with Parkinson's Disease by examining multiregional gene expression from normal brain and brain of Parkinson's Disease. The present also identifies the changes in gene expression associated with Parkinson's Disease by examining the expression of genes from normal blood and from the blood of patients with Parkinson's Disease. In another aspect, the present invention identifies expression profiles which serve as useful diagnostic markers as well as markers that can be used to monitor disease states, disease progression, drug toxicity, drug efficacy and drug metabolism. | 11-25-2010 |
20100305208 | GASTRIC RETENTION CONTROLLED DRUG DELIVERY SYSTEM - The present invention provides a gastric retention controlled drug delivery system comprising:
| 12-02-2010 |
20100317738 | COMPOSITIONS AND METHODS FOR TREATING CONDITIONS ASSOCIATED WITH NEURONAL DYSFUNCTION - The present invention relates to compositions and methods for the treating and empirically investigating conditions associated with neuronal dysfunction (e.g., chronic pain, epileptic neuronal activity). In particular, the present invention provides compositions and methods for using flufenamic acid in the treatment and empirical investigation of conditions associated with neuronal dysfunction (e.g., chronic pain, epileptic neuronal activity). | 12-16-2010 |
20100324141 | HIGH PURITY 2-[4-(3- OR 2-FLUOROBENZYLOXY)BENZYLAMINO]PROPANAMIDES AND METHODS OF USE THEREOF - A process for obtaining therapeutically active 2-[4-(3- and 2-(fluorobenzyloxy)benzylamino]-propanamides and their salts with pharmaceutically acceptable acids with a high degree of purity, i.e. with a content of dibenzyl derivatives impurities lower than 0.03% by weight. The process is carried out by submitting a Schiff base intermediate to a reduction reaction with a reducing agent in an amount of organic solvent to allow the formation (and presence during a substantial portion of the reduction reaction) of a suspension of the Schiff base. | 12-23-2010 |
20110015270 | Novel NIDDM Regimen - The present invention relates to the use of a short-acting oral hypoglycemic agent and to a novel regimen in the treatment of type 2 diabetes in which the endogenous secretion of insulin is stimulated in connection with meals by administering in connection with the meals a short-acting oral hypoglycaemic agent. Also, the present invention relates to a method of achieving significantly improvement in the glycaemic control by a combined use of repaglinide and metformin in NIDDM patients poorly controlled on metformin alone. | 01-20-2011 |
20110028554 | PHARMACEUTICAL COMPOSITIONS COMPRISING DIIODOTHYRONINE AND THEIR THERAPEUTIC USE - The present invention relates to a pharmaceutical composition comprising, as active substance, at least one hormone chosen among 3,5-diiodothyronine (3,5-T2), 3′,3-diiodothyronine (3′,3-T2), 3′,5-diiodothyronine (3′,5-T2), 3′-iodothyronine (3′-T), 3-iodothyronine (3-T) or 5-iodothyronine (5-T), in association with a pharmaceutically acceptable vehicle. | 02-03-2011 |
20110028555 | Antiinflammatory and Analgesic Preparation for External Use - It is intended to provide an antiinflammatory and analgesic preparation for external use whereby side effects of a nonsteroidal antiinflammatory and analgesic drug on the skin can be regulated, the nonsteroidal antiinflammatory and analgesic drug can be prevented from degeneration with time due to a dibenzoylmethane derivative contained as an UV absorbent therein, the dibenzoylmethane derivative can be prevented from crystallization and sedimentation due to an oily phase component contained therein, and the inherent effects of the nonsteroidal anti-inflammatory and analgesic drug can be fully exerted without showing skin irritation caused by the oily phase component, an emulsifier and a thickener. The above problem can be solved by providing an antiinflammatory and analgesic preparation for external use which comprises a base for external use containing an oily phase component, a nonsteroidal antiinflammatory and analgesic drug and a dibenzoylmethane derivative and in which the total amount of fatty acid esters in the oily phase component is at least thrice as much as the content of the dibenzoylmethane derivative. | 02-03-2011 |
20110054031 | Ophthalmic NSAIDS as Adjuvants - The disclosure provides methods and ophthalmic NSAIDs as adjuvants to VEGF inhibitors useful for treating retinal disorders, including but not limited to wet AMD, diabetic retinopathy, diabetic macular edema, central retinal vein occlusion, and branch retinal vein occlusion. | 03-03-2011 |
20110092595 | Compositions and Methods for Treating Lung Cancer - Embodiments of the present invention provide compositions and methods for treating lung cancer, including small cell and non-small cell lung cancer that may express HIF-1a by administering a therapeutically effective amount of PX-478. | 04-21-2011 |
20110092596 | POLYMORPHS OF BROMFENAC SODIUM AND METHODS FOR PREPARING BROMFENAC SODIUM POLYMORPHS - Different polymorphs of bromfenac sodium may be prepared and interconverted using crystallization/recrystallization, drying and/or hydration techniques. | 04-21-2011 |
20110092597 | METHOD FOR TREATING HERPES VIRUS INFECTION - The present invention is directed to a method for inhibiting herpes viral activity in a subject, by administering to the subject in need thereof an active ingredient consisting essentially of an effective amount of diclofenac (for example, 3-7% w/v) or a pharmaceutically acceptable salt thereof. | 04-21-2011 |
20110105613 | MOISTURE RESISTANT CONTAINER SYSTEMS FOR RAPIDLY BIOAVAILABLE DOSAGE FORMS - Provided are rapidly bioavailable solid oral dosage forms of acute pain medications, and moisture resistant packaging that enables the formulation of such rapidly bioavailable dosage forms. | 05-05-2011 |
20110105614 | High Concentration Baclofen Preparations - Stable aqueous solutions comprising concentrations of baclofen in the range of greater than 2.0 mg/mL up to about 10 mg/mL are disclosed. These solutions can be used as pharmaceuticals for parenteral or oral administration. The invention also provides methods of preparing said stable aqueous baclofen solutions. | 05-05-2011 |
20110105615 | TABLET QUICKLY DISINTEGRATING IN THE ORAL CAVITY AND METHOD FOR PRODUCING THE SAME - The present invention relates to a tablet which is rapidly disintegrated in an oral cavity containing an active ingredient at a high content and a production method thereof. That is, the present invention provides a tablet which is rapidly disintegrated in an oral cavity containing an active ingredient in not less than 25% of the total weight, having a disintegration time of within 40 seconds and an absolute hardness of 1.8 N/mm | 05-05-2011 |
20110118353 | METHOD OF HORMONE SUPPRESSION IN HUMANS - The present invention relates to a glycine transporter-1 inhibitor having the formula (I) wherein X is 1-3 substituents selected from H, halogen, methyl, methoxy, trifluoromethyl and trifluoromethoxy and Y is 1-3 substituents selected from H, methyl and halogen or a pharmaceutically acceptable salt thereof for use in a treatment in humans to suppress the level of one or more hormone selected from luteinizing hormone, follicle-stimulating hormone, estradiol and testosterone. The present invention further relates to such a glycine transporter-1 inhibitor as part of a contraceptive regimen or as a treatment for hypersexuality. | 05-19-2011 |
20110136911 | TREATMENT OF SEPSIS AND INHIBITION OF MIF BY D-T4 - Methods and compositions are disclosed for the use of dextrothyroxine (D-T4) to treat sepsis, inflammation, and conditions and diseases in which it is desirable to inhibit macrophage migration inhibitory factor (MIF). | 06-09-2011 |
20110144206 | USE OF A COX-2 INHIBITOR FOR THE TREATMENT OF A COX-2 DEPENDENT DISORDER IN A PATIENT NOT CARRYING HLA ALLELES ASSOCIATED WITH HEPATOTOXICITY - This disclosure relates to a method of determining the presence of at least one HLA allele, preferably selected from the group consisting of DQA1*0102, DRB1*1501, DQB1*0602 and DRB5*0101 to assess whether a patient is at risk for developing hepatotoxicity upon administration of the COX-2 inhibitor lumiracoxib. Also disclosed is the use of a kit for carrying out this method. The disclosure also relates to a method of treating cyclooxygenase-2 dependent disorders with lumiracoxib in a subject that is not a carrier of one or more HLA alleles, preferably selected from the group consisting of DQA1*0102, DRB1*1501, DQB1*0602 and DRB5*0101. | 06-16-2011 |
20110178178 | Treatment of Motor Fluctuations - The invention relates to the use of compounds that enhance 5-hydroxytryptamine 1a receptor activity, or activation (e.g. a selective 5-hydroxytryptamine 1a receptor agonists) for preventing or reducing motor fluctuations associated with dopamine replacement therapy. | 07-21-2011 |
20110201684 | EP2 Agonist from Non-Prostanoid Structures Designed as PGE2 Antagonists - A method of treating ocular hypertension, lowering intraocular pressure, pain or inflammation, comprising administering to a mammal a pharmaceutical composition of an EP | 08-18-2011 |
20110218247 | FORMULATIONS OF LOW DOSE DICLOFENAC AND BETA-CYCLODEXTRIN - The present invention is directed to a pharmaceutical composition containing a unit dose of a diclofenac compound effective to induce analgesia; and a beta-cyclodextrin compound; wherein the dose of the diclofenac compound is less than 10 mg. The present invention is also directed to methods of treating a subject in need of analgesia with the pharmaceutical compositions of the invention. | 09-08-2011 |
20110237674 | TOPICAL NSAID COMPOSITIONS HAVING SENSATE COMPONENT - Topical pharmaceutical compositions comprising a topically administrable NSAID, a sensate agent and optionally a self-warming system, when administered to a patient in need thereof, provide significant improvements in the rate and extent of skin absorption, as well as impart a sensation of rapid and complete relief from pain. | 09-29-2011 |
20110269836 | INTRATHECAL BACLOFEN PHARMACEUTICAL DOSAGE FORMS AND RELATED DELIVERY SYSTEM - According to the subject invention, there is disclosed, a dosage and packaging configuration which includes the use of color-coded pre-filled syringes and vials to fill and refill infusion systems with existing and new dosage forms of intrathecal baclofen. | 11-03-2011 |
20110275717 | PHARMACEUTICAL FORMULATION COMPRISING DICLOFENAC - The present invention relates to a pharmaceutical formulation comprising a pharmaceutically acceptable salt of diclofenac, at least one polyoxyalkylene ester of a hydroxy fatty acid, water, and, optionally, a co-solvent. | 11-10-2011 |
20110281947 | METHODS OF ADMINISTERING DICLOFENAC COMPOSITIONS FOR TREATING PHOTODAMAGED SKIN - A method of treating at least one dermatological disorder selected from the group consisting of photodamage-induced wrinkles, rosacea, and acne, includes: (a) providing a composition containing 1-3 wt. % diclofenac or a salt thereof, 0.5-1.5 wt. % benzyl alcohol; 10-30 wt. % PEG monomethyl ether, 0.1-3.0 wt. % sodium hyaluronate; and 70-80 wt. % water; and (b) applying the composition to skin of a person in need of the treating in an amount effective to treat the at least one dermatological disorder. | 11-17-2011 |
20110288174 | Monohydrate of 4-(phenyl)ethyl]-amino}methyl)benzoic acid - The invention relates to novel forms of 4-({(4-carboxybutyl) [2-(2-{[4-(2-phenylethyl)benzyl]oxy}phenyl)ethyl]amino}methyl)benzoic acid, in particular to the monohydrate in form A, to processes for their preparation, to medicaments comprising them and to their use for fighting diseases. | 11-24-2011 |
20110294889 | Infusion and Injection Solution of Levodopa - An infusion or injection solution of Levodopa containing at least 10 mg/mL of Levodopa, or at least 5 mg/mL of Levodopa together with at least 0.5 mg/mL of at least one inhibitor of a Levodopa-metabolising enzyme is disclosed. The solution further contains a buffer, a physiologically acceptable sugar, such as glucose, a physiologically acceptable acid, such as hydrochloric acid, and optionally a stabilizer, and has a pH of lower than or equal to 6. There are also described a disposable syringe containing an infusion or injection solution of Levodopa, optionally together with a Levodopa-metabolising enzyme, and an infusion pump cassette containing an infusion or injection solution of Levodopa optionally together with a Levodopa-metabolising enzyme. | 12-01-2011 |
20110319490 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME - A method for a prevention and/or treatment of irritable bowel syndrome or amelioration of a symptom thereof in a subject, comprises administering to said subject an effective amount of a compound of formula I: | 12-29-2011 |
20120004305 | EXTERNAL PREPARATION CONTAINING ANALGESIC/ANTI-INFLAMMATORY AGENT - An external preparation containing the following components (A), (B), (C), and (D):
| 01-05-2012 |
20120004306 | EXTERNAL PREPARATION CONTAINING ANALGESIC/ANTI-INFLAMMATORY AGENT - An external preparation containing the following components (A), (B), and (C):
| 01-05-2012 |
20120010292 | MODIFICATION I OF 4-(PHENYL)ETHYL]-AMINO}METHYL)BENZOIC ACID - The invention relates to novel forms of 4-({(4-carboxybutyl)[2-(2-{[4-(2-phenyl-ethyl)benzyl]oxy}phenyl)ethyl]amino}methyl)benzoic acid, in particular to the modification I, to processes for their preparation, to medicaments comprising them and to their use for fighting diseases. | 01-12-2012 |
20120010293 | DROXIDOPA AND PHARMACEUTICAL COMPOSITION THEREOF FOR THE TREATMENT OF MOOD DISORDERS, SLEEP DISORDERS, OR ATTENTION DEFICIT DISORDERS - The present invention provides pharmaceutical compositions comprising droxidopa alone, or in combination with one or more further active ingredients, for the treatment of conditions, such as mood disorders, sleep disorders, or attention deficit disorders. In certain embodiments, the compositions useful in the methods of the invention comprise droxidopa and a compound selected from the group consisting of DOPA decarboxylase inhibiting compounds, catechol-O-methyltransferase inhibiting compounds, cholinesterase inhibiting compounds, monoamine oxidase inhibiting compounds, norepinephrine reuptake inhibiting compounds, selective serotonin reuptake inhibiting compounds, tricyclic antidepressant compounds, serotonin norepinephrine reuptake inhibiting compounds, norepinephrine dopamine reuptake inhibiting compound, noradrenergic and specific serotonergic antidepressants, and combinations thereof. The inventive compositions are particularly useful in the treatment of depression, narcolepsy, insomnia, and Attention Deficit/Hyperactivity Disorder (AD/HD). | 01-12-2012 |
20120035265 | COMPOSITIONS, METHODS, AND DEVICES FOR THE TREATMENT OF DYSMENORRHEA - A method for a prevention and/or treatment of dysmenorrhea or amelioration of a symptom thereof in a subject, comprising administering to said subject an effective amount of a compound of formula I: | 02-09-2012 |
20120065267 | COMPOSITIONS INCLUDING 3,5-L-T2 AND METHODS OF USE THEREOF - Compositions containing 3,5-L-T2 ((2S)-2-amino-3-[4-(4-hydroxyphenoxy)-3,5-diiodophenyl]propanoic acid) and methods for use thereof. Among other functions presented herein, 3,5-L-T2 can lower cholesterol via a mechanism that is independent of LDL receptor function. Disclosed compositions may include one or more additional active agents, such as, but not limited to, thyroid hormones other than 3,5-L-T2, cholesterol lowering agents, anti-diabetes agents, anti-hypertensives, vasodilators, inotropic agents, anti-coagulants, anti-anginals, anti-arrhythmics, leptin, leptin analogues, and adipokines, a vitamin and mineral composition. Disclosed methods include, but are not limited to, methods for treating hypercholesterolemia in a subject, and methods for treating at least one of metabolic syndrome, hypothyroidism, or thyroid suppression. | 03-15-2012 |
20120065268 | High Concentration Baclofen Preparations - Stable aqueous solutions comprising concentrations of baclofen in the range of greater than 2.0 mg/mL up to about 10 mg/mL are disclosed. These solutions can be used as pharmaceuticals for parenteral or oral administration. The invention also provides methods of preparing said stable aqueous baclofen solutions. | 03-15-2012 |
20120095101 | AQUEOUS INTRAOCULAR PENETRATION-PROMOTING EYE DROP - An aqueous eye drop comprising 2-amino-3-(4-bromobenzoyl)phenylacetic acid or its pharmacologically acceptable salt or a hydrate thereof and an organic amine (for example, aminoethylsulfonic acid or trometamol) or a salt thereof is useful as an eye drop for once a day administration for treating inflammatory diseases of the external segment or the anterior segment of the eyes, since such aqueous eye drop can maintain a therapeutically effective concentration of 2-amino-3-(4-bromobenzoyl)phenylacetic acid in anterior aqueous humor for at least 24 hours by once a day administration. | 04-19-2012 |
20120101164 | ABSCISSION AND CROP STORAGE UNIT - A composition comprising a compound selected from an auxin, an auxin precursor, an auxin metabolite or a derivative of said auxin, auxin precursor or auxin metabolite or a mixture thereof and optionally acetaminophen or a derivative thereof for improving post-harvest storability of crops. | 04-26-2012 |
20120115957 | AQUEOUS LIQUID PREPARATION CONTAINING 2-AMINO-3-(4-BROMOBENZOYL)PHENYLACETIC ACID - An aqueous liquid preparation of the present invention containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid or its pharmacologically acceptable salt or a hydrate thereof, an alkyl aryl polyether alcohol type polymer such as tyloxapol, or a polyethylene glycol fatty acid ester such as polyethylene glycol monostearate is stable. Since even in the case where a preservative is incorporated into said aqueous liquid preparation, the preservative exhibits a sufficient preservative effect for a long time, said aqueous liquid preparation in the form of an eye drop is useful for the treatment of blepharitis, conjunctivitis, scleritis, and postoperative inflammation. Also, the aqueous liquid preparation of the present invention in the form of a nasal drop is useful for the treatment of allergic rhinitis and inflammatory rhinitis (e.g. chronic rhinitis, hypertrophic rhinitis, nasal polyp, etc.). | 05-10-2012 |
20120122986 | Methods of Treating Fragile X Syndrome - Subjects having fragile X syndrome are treated with a composition that includes gamma-aminobutyric acid agonists. The gamma-aminobutyric acid agonist (GABA) can be a GABA(B) agonist, such as baclofen, including racemic and R-baclofen. | 05-17-2012 |
20120129940 | METHODS OF TREATING AUTISM - Subjects having autism are treated with a composition that includes gamma-aminobutyric acid agonists. The gamma-aminobutyric acid agonist (GABA) can be a GABA(B) agonist, such as baclofen. | 05-24-2012 |
20120142779 | STABLE INJECTABLE COMPOSITIONS - This invention relates to a stable parenteral aqueous solutions comprising either (a) diclofenac or a pharmaceutically acceptable diclofenac salt and a cyclodextrin, or (b) an inclusion complex of diclofenac or a pharmaceutically acceptable diclofenac salt and a cyclodextrin, or a mixture of (a) and (b), which are suitable for intramuscular and intravenous administration. The solutions contain diclofenac or diclofenac salt, cyclodextrin, and an antioxidant selected from monothioglycerol, or a combination of ethylene diamine tetra-acetic acid and N-acetyl-cysteine. | 06-07-2012 |
20120157536 | COMPOSITION FOR TRANSDERMAL ADMINISTRATION OF NON-STEROIDAL ANTI-FLAMMATORY DRUG - This invention pertains to compositions and method for transdermal administration of non-steroidal anti-inflammatory and analgesic drugs (NSAID) for the treatment of inflammation and pain caused by conditions such as arthritis, degenerative joint disease, minor strains, pains, and contusions. This invention particularly relates to transdermal compositions comprising an NSAID, a bioadhesive graft copolymer, and a skin penetration enhancer, selected from pyrrolidone or its derivatives and dialkyl sulfoxides and combinations thereof. | 06-21-2012 |
20120165409 | WRINKLE-IMPROVING AGENT - A wrinkle-improving agent that has an effect of improving wrinkles, that does not entail problems of safety or pain even when applied to the skin, and that contains a very safe substance as an active component. A discovery was made that N-benzoyl-β-alanine, other specific β-alanine derivatives, and salts thereof have a wrinkle-improving effect, whereby a wrinkle-improving agent containing as an active component one, two, or more types of compounds selected from the group composed of these specific β-alanine derivatives and the salts thereof was developed. | 06-28-2012 |
20120190748 | GREATER UTILITY WITH THYROID HORMONE - Formulations and delivery systems that include a thyroid hormone active agent consisting essentially of T4 should reduce fluctuations in delivery of thyroid hormone. | 07-26-2012 |
20120208886 | Moisture Resistant Container Systems for Rapidly Bioavailable Dosage Forms - Provided are rapidly bioavailable solid oral dosage forms of acute pain medications, and moisture resistant packaging that enables the formulation of such rapidly bioavailable dosage forms. | 08-16-2012 |
20120289602 | PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING BURN INJURIES - The present invention relates to a pharmaceutical composition and the method of use for treating or preventing burn injury in patients or subjects in need, including the compound represented by the specific chemical formula as an active ingredient or its pharmaceutically acceptable salts or solvates. | 11-15-2012 |
20120295978 | DICLOFENAC GEL - The present invention provides a gel formulation comprising diclofenac sodium which has superior transdermal flux properties, which may be used for the topical treatment of pain, such as in osteoarthritis. | 11-22-2012 |
20120322874 | Pharmaceutical Uses - The invention provides a method of treating an angiogenesis-mediated ocular disorder, e.g. ocular neovascularisation, retinal neovascularisation, including neovascularisation following injury or infection, retrolental fibroplasias, and neovascular glaucoma, age-related macular degeneration, diabetic retinopathy, pathologic myopia, ocular histoplasmosis, neovascular glaucoma, retinopathy of prematurity, the after effects of corneal transplantation, control of postsurgical ocular inflammation (e.g. after cataract surgery), cystoid macular edema (CME), herpes keratitis, in a subject in need of such treatment which comprises administering to the subject an effective amount of a COX-2 inhibitor of formula I | 12-20-2012 |
20130005813 | Compounds and their Salts Specific to the PPAR Receptors and the EGF Receptors and their Use in the Medical Field - The present invention relates to compounds comprising the general formula (I), in which R | 01-03-2013 |
20130005814 | METHODS AND COMPOSITIONS FOR FACILITATING WEIGHT LOSS BY ADMINISTRATION OF THYROID HORMONES - The present invention provides methods and compositions for facilitating weight loss in subjects who are undergoing a weight loss regimen by administration of thyroid hormones, for example, T | 01-03-2013 |
20130005815 | AQUEOUS INTRAOCULAR PENETRATION-PROMOTING EYE DROP - An aqueous eye drop comprising 2-amino-3-(4-bromobenzoyl)phenylacetic acid or its pharmacologically acceptable salt or a hydrate thereof and an organic amine (for example, aminoethylsulfonic acid or trometamol) or a salt thereof is useful as an eye drop for once a day administration for treating inflammatory diseases of the external segment or the anterior segment of the eyes, since such aqueous eye drop can maintain a therapeutically effective concentration of 2-amino-3-(4-bromobenzoyl)phenylacetic acid in anterior aqueous humor for at least 24 hours by once a day administration. | 01-03-2013 |
20130012585 | Phenylacetic Acid Derivatives - Compounds of formula (I) pharmaceutically acceptable salts thereof; and pharmaceutically acceptable esters thereof; which are useful for the treatment of COX-2 dependent disorders. | 01-10-2013 |
20130012586 | Methods of Treating Fragile X Syndrome - Subjects having fragile X syndrome are treated with a composition that includes gamma-aminobutyric acid agonists. The gamma-aminobutyric acid agonist (GABA) can be a GABA(B) agonist, such as baclofen, including racemic and R-baclofen. | 01-10-2013 |
20130012587 | Methods of Treating Autism - Subjects having autism are treated with a composition that includes gamma-aminobutyric acid agonists. The gamma-aminobutyric acid agonist (GABA) can be a GABA(B) agonist, such as baclofen. | 01-10-2013 |
20130023588 | POLYMORPHS OF BROMFENAC SODIUM AND METHODS FOR PREPARING BROMFENAC SODIUM POLYMORPHS - Different polymorphs of bromfenac sodium may be prepared and interconverted using crystallization/recrystallization, drying and/or hydration techniques. | 01-24-2013 |
20130041034 | Treatment of pain with topical diclofenac compounds - The field involves compositions useful for pain relief, including diclofenac solution and gel formulations, in particular methods of use thereof, articles of manufacture and kits that provide novel preclinical, clinical and other information to users. | 02-14-2013 |
20130053445 | Levothyroxine Formulations - A levothyroxine composition includes levothyroxine sodium and mannitol. The composition is a solid. The composition may include from 100 to 500 micrograms levothyroxine sodium and from 1 to 5 milligrams mannitol. The composition may include from 100 to 200 micrograms levothyroxine sodium, and the mass ratio of mannitol to levothyroxine sodium in the composition may be at most 40:1. The composition may include about 500 micrograms levothyroxine sodium, and the mass ratio of mannitol to levothyroxine sodium in the composition may be at most 10:1. | 02-28-2013 |
20130059915 | TREATMENT OF PAIN WITH TOPICAL DICLOFENAC - The field involves compositions useful for pain relief, including diclofenac solution and gel formulations, in particular methods of use thereof, articles of manufacture and kits that provide novel preclinical, clinical and other information to users. | 03-07-2013 |
20130065962 | Compounds For Use In The Treatment Of Diseases - The present invention relates to a compound of the general formula (III): | 03-14-2013 |
20130090384 | AQUEOUS LIQUID PREPARATION CONTAINING 2-AMINO-3-(4-BROMOBENZOYL)PHENYLACETIC ACID - An aqueous liquid preparation of the present invention containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid or its pharmacologically acceptable salt or a hydrate thereof, an alkyl aryl polyether alcohol type polymer such as tyloxapol, or a polyethylene glycol fatty acid ester such as polyethylene glycol monostearate is stable. Since even in the case where a preservative is incorporated into said aqueous liquid preparation, the preservative exhibits a sufficient preservative effect for a long time, said aqueous liquid preparation in the form of an eye drop is useful for the treatment of blepharitis, conjunctivitis, scleritis, and postoperative inflammation. Also, the aqueous liquid preparation of the present invention in the form of a nasal drop is useful for the treatment of allergic rhinitis and inflammatory rhinitis (e.g. chronic rhinitis, hypertrophic rhinitis, nasal polyp, etc.). | 04-11-2013 |
20130096199 | BROMFENAC BIOAVAILABILITY - Formulations and methods that provided enhanced bromfenac penetration into ocular tissue when topically administered, compared to the currently available BROMDAY™ formulation and method when topically administered. The formulations and methods did so while retaining the patient convenience of a once-daily administration and advantageously lowered the bromfenac concentration dosed to the patient. | 04-18-2013 |
20130109755 | Baclofen Formulations and Methods for Making Same | 05-02-2013 |
20130131176 | High Concentration Baclofen Preparations - Stable aqueous solutions comprising concentrations of baclofen in the range of greater than 2.0 mg/mL up to about 10 mg/mL are disclosed. These solutions can be used as pharmaceuticals for parenteral or oral administration. The invention also provides methods of preparing said stable aqueous baclofen solutions. | 05-23-2013 |
20130190402 | Methods Of Treating Autism With mGluR5 Antagonists - mGluR5 antagonists are used for the treatment of autism. The human treated by the methods of the invention can also have fragile X syndrome, epilepsy and anxiety. | 07-25-2013 |
20130197089 | COMPOSITIONS FOR THE TREATMENT OF ACTINIC KERATOSIS - Ibuprofen can be used in the prevention and treatment of actinic keratosis. | 08-01-2013 |
20130197090 | POSTURAL STABILITY AND INCIDENT FUNCTIONS IN PATIENTS - The present invention provides methods and systems for reducing falls in patients that are recurrent fallers. Specifically, the compositions, systems, and methods can relate to Parkinson's disease patients, particularly such patients that are suffering from neurogenic orthostatic hypotension. The compositions, systems, and methods comprise the use of droxidopa, optionally in combination with a further active agent. Administration of droxidopa has been found to reduce the mean number of falls per patient per week, as well as provide improvements in the patient's Hoehn and Yahr rating scale score, which is indicative of improvements in postural stability, and provide improvements in the patient's Unified Parkinson's disease Rating Scale score, which is indicative of improvements in the severity of motor and/or non-motor symptoms of Parkinson's disease. | 08-01-2013 |
20130197091 | USE OF ADRENERGIC BETA-E-RECEPTOR BLOCKERS IN CANCER TREATMENT - A method for treating an cancer disease is disclosed comprising administering to a subject a pharmaceutical composition comprising an adrenergic beta-3-receptor blocker. | 08-01-2013 |
20130197092 | Novel Non-Aqueous Topical Solution of Diclofenac and Process for Preparing the Same - A novel non-aqueous topical solution composition of pharmaceutically acceptable salt of diclofenac is disclosed. The non-aqueous topical solution composition comprises therapeutically effective amount of pharmaceutically acceptable salt of diclofenac, solublizer, penetration enhancer and solvent, and optionally a humectant, counter irritant, additional penetration enhancer and anti-oxidants and a process for preparing the same. | 08-01-2013 |
20130217773 | Method and Device for assistance in delivery of medication, and Formulas - This invention is designed for the convenient and reliable delivery of predetermined doses of topical therapeutic medications applied to the skin. | 08-22-2013 |
20130245122 | DICLOFENAC FORMULATIONS AND METHODS OF USE - Methods and formulations are provided for treating migraine and other acute pain episodes using diclofenac, and formulations of diclofenac that provide both rapid and sustained relief from acute pain. Methods and formulations are also provided for treating symptoms that often accompany migraine and acute pain such as photophobia, phonophobia, nausea and vomiting. | 09-19-2013 |
20130253061 | METHOD OF DROXIDOPA SYNTHESIS - The present application relates to a novel method of preparing L-threo-dihydroxyphenylserine (droxidopa). Specifically, the application is directed to a method of preparing droxidopa via a deprotection step that is an alternative to deprotection steps that have been previously disclosed. The new deprotection strategy is advantageous in that it avoids the need to use hydrogenolysis or hydrazine. | 09-26-2013 |
20130261186 | Methods of Treating Autism - Subjects having autism are treated with a composition that includes gamma-aminobutyric acid agonists. The gamma-aminobutyric acid agonist (GABA) can be a GABA(B) agonist, such as baclofen. The humans can be administered the GABA(B) agonist in a single dose or multiple doses. | 10-03-2013 |
20130267601 | Method for prevention of alzheimer's disease - A method for prevention of Alzheimer's Disease (AD) is presented. The principal cause of AD is a deficiency at the cellular level of the human brain, of the effects of the active form of thyroid hormone, tri-iodothyronine (T3). Lifelong T3 replacement, beginning in early to mid life and, in some cases later, overcomes these blocks to T3 production and actions and prevents AD in a majority of the sub-types of AD. | 10-10-2013 |
20130267602 | MOISTURE RESISTANT CONTAINER SYSTEMS FOR RAPIDLY BIOAVAILABLE DOSAGE FORMS - Provided are rapidly bioavailable solid oral dosage forms of acute pain medications, and moisture resistant packaging that enables the formulation of such rapidly bioavailable dosage forms. | 10-10-2013 |
20130281536 | 3,5,3'-Triiodothyronine Sulfate As Thyromimetic Agent And Pharmaceutical Formulations Thereof - The invention regards the use of triiodothyronine sulfate, commonly named T | 10-24-2013 |
20130281537 | AQUEOUS LIQUID BROMFENAC COMPOSITION HAVING PRESERVATIVE EFFICACY - An aqueous liquid bromfenac composition containing (a) bromfenac or a salt thereof and (b) benzalkonium chloride, characterized by that the composition has preservative efficacy and that the concentration of (b) benzalkonium chloride is higher than 0.0005% and lower than 0.005%. | 10-24-2013 |
20130289120 | POLYMORPHS OF BROMFENAC SODIUM AND METHODS FOR PREPARING BROMFENAC SODIUM POLYMORPHS - Different polymorphs of bromfenac sodium may be prepared and interconverted using crystallization/recrystallization, drying and/or hydration techniques. | 10-31-2013 |
20130331451 | High Concentration Baclofen Preparations - Stable aqueous solutions comprising concentrations of baclofen in the range of greater than 2.0 mg/mL up to about 10 mg/mL are disclosed. These solutions can be used as pharmaceuticals for parenteral or oral administration. The invention also provides methods of preparing said stable aqueous baclofen solutions. | 12-12-2013 |
20140005269 | POLYMERIC MATRIX OF POLYMER-LIPID NANOPARTICLES AS A PHARMACEUTICAL DOSAGE FORM | 01-02-2014 |
20140011880 | POLYMORPHS OF BROMFENAC SODIUM AND METHODS FOR PREPARING BROMFENAC SODIUM POLYMORPHS - Different polymorphs of bromfenac sodium may be prepared and interconverted using crystallization/recrystallization, drying and/or hydration techniques. | 01-09-2014 |
20140018426 | FOOD OR BEVERAGE COMPOSITION FORTIFIED WITH THYRONAMINES AND/OR THYRONAMINE PRECURSORS - Food or beverage compositions fortified with thyronines and/or thyronamines, processes for increasing T2, T1AM, and/or T0AM in a subject by administering a food or beverage composition that is fortified with at least one thyronine and/or thyronamine compound, and processes for promoting a healthy state by administering a food or beverage composition to a subject that is fortified with at least one thyronine and/or thyronamine compound. Increased levels of T2, T1AM, and/or T0AM in a subject can be associated with at least one of healthy cholesterol levels, healthy triglyceride levels, healthy blood sugar levels, cardiovascular health, healthy sleep patterns, healthy mood, healthy skin, healthy nails, or healthy endocrine function and/or a number of other markers of associated with general health and well-being. | 01-16-2014 |
20140018427 | DICLOFENAC TOPICAL FORMULATION - The present invention provides a gel formulation comprising diclofenac sodium which has superior transdermal flux properties, which may be used for the topical treatment of pain, such as in osteoarthritis. | 01-16-2014 |
20140018428 | POLYMORPHS OF BROMFENAC SODIUM AND METHODS FOR PREPARING BROMFENAC SODIUM POLYMORPHS - Different polymorphs of bromfenac sodium may be prepared and interconverted using crystallization/recrystallization, drying and/or hydration techniques. | 01-16-2014 |
20140039056 | BROMFENAC ORGANIC SALTS AND PREPARATION METHOD, COMPOSITION AND USE THEREOF - Provided are bromfenac organic salts and preparation method, composition and use thereof. The bromfenac organic salt has the structure as shown in the following Formula I, wherein A represents an organic base. Also provided are a method for the preparation of the bromfenac organic salt, a composition comprising the bromfenac organic salts, a use of the bromfenac organic salts or the composition thereof in manufacture of a medicament for treatment and/or prophylaxis of an inflammation or for analgesia, and a method for treatment and/or prophylaxis of an inflammation or for analgesia. | 02-06-2014 |
20140045942 | TOPICAL COMPOSITION - The invention relates to beneficial topical pharmaceutical compositions comprising diclofenac sodium salt in unusually low amounts. The compositions represent opaque emulsion-gels, in which diclofenac is kept fully dissolved. | 02-13-2014 |
20140051758 | HIGH PURITY 2-[4-(3- OR 2-FLUOROBENZYLOXY)BENZYLAMINO] PROPANAMIDES AND METHODS OF USE THEREOF - A process for obtaining therapeutically active 2-[4-(3- and 2-(fluorobenzyloxy)benzylamino]propanamides, and their salts with pharmaceutically acceptable acids with high purity degree, in particular, with a content of dibenzyl derivatives impurities lower than 0.03%, preferably lower than 0.01% by weight. The process is carried out by submitting the Schiff bases intermediates 2-[4-(3- and 2-fluorobenzyloxy)benzylideneamino]propanamides to a reduction reaction with a reducing agent selected from sodium borohydride and potassium borohydride in an appropriate amount of an organic solvent selected from C | 02-20-2014 |
20140057983 | EYE DROPS FOR TREATMENT OF CONJUNCTIVOCHALASIS - An ophthalmic preparation and method, usable to treat conjunctivochalasis. The ophthalmic preparation comprises an aqueous solution of glycerol. The preparation may also include additional components including high molecular weight polymers for viscosity control and pharmacologically active substances. The method includes administering an ophthalmic preparation including an aqueous solution of glycerol to a patient. | 02-27-2014 |
20140066513 | METHODS FOR COMPOSITIONS FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME - A method for a prevention and/or treatment of irritable bowel syndrome or amelioration of a symptom thereof in a subject, comprises administering to said subject an effective amount of a compound of formula I: | 03-06-2014 |
20140073695 | METHOD FOR THE PREPARATION OF A LEVOTHYROXINE SOLUTION - Levothyroxine, also known as L-thyroxine, synthetic T4, or 3,5,3′,5′-tetraiodo-L-thyronine, CAS number 51-48-9, is a synthetic form of thyroxine, used as a hormone substitute for patients with thyroid conditions. The invention relates to a method for the preparation of an oral levothyroxine composition. The method according to the invention results in liquid levothyroxine formulations that have improved storage stability compared to known liquid levothyroxine formulations. | 03-13-2014 |
20140080911 | Polymeric Adhesive Matrix with Salified Carboxylic Groups for Transdermal Use - Polymeric matrices for the controlled release of medicaments for the topical transdermal use comprising copolymers of acrylic and/or methacrylic acid or esters thereof having a Tg lower than 0.degree. C., whose free carboxy groups are salified with compatible organic or inorganic bases. The matrices of the invention allow to prepare therapeutical systems for the controlled-release of active principles through the transdermal route, thus solving stability, solubility and/or bioavailability problems of the active ingredient within the matrix. | 03-20-2014 |
20140100285 | COMPOSITIONS OF PERCUTANEOUS ADMINISTRATION OF PHYSIOLOGICALLY ACTIVE AGENTS - Compositions intended for the percutaneous administration of physiologically active agents, e.g. drugs or a veterinary agents, are disclosed. Said compositions are characterized forming a non-sticky, very flexible film that ‘has excellent long term efficacy. | 04-10-2014 |
20140107208 | BIOMARKERS PREDICTIVE FOR CLINICAL RESPONSE FOR GLATIRAMER ACETATE - The present invention provides a method for treating a human subject afflicted with multiple sclerosis or a single clinical attack consistent with multiple sclerosis with a pharmaceutical composition comprising glatiramer acetate and a pharmaceutically acceptable carrier, comprising the steps of:
| 04-17-2014 |
20140107209 | FORMULATIONS OF LOW DOSE DICLOFENAC AND BETA-CYCLODEXTRIN - The present invention is directed to a pharmaceutical composition containing a unit dose of a diclofenac compound effective to induce analgesia; and a beta-cyclodextrin compound; wherein the dose of the diclofenac compound is less than 10 mg. The present invention is also directed to methods of treating a subject in need of analgesia with the pharmaceutical compositions of the invention. | 04-17-2014 |
20140107210 | METHOD OF TREATING POST-SURGICAL ACUTE PAIN - A method is provided for treating pain in patients recovering from post-surgical trauma by administering between about 13 to about 30 mg of diclofenac potassium in a liquid dispersible formulation over a period of at least 24 hours, wherein the daily total amount of diclofenac potassium administered is less than or equal to about 100 mg. The method is particularly useful in treating acute pain in bunionectomy patients. | 04-17-2014 |
20140113970 | DISPENSING SYSTEM - The invention provides systems and methods for controlled dispensing of topical analgesics contained in a metered dispensing system. The systems and method are useful for treating signs and symptoms of osteoarthritis. The method includes depressing a hand pump to dispense a dose of a topical pain reliever in a viscous solution from the hand pump, wherein the hand pump is configured to dispense the dose within a tolerance specified by a corresponding label approved by a government regulatory agency; and spreading the topical solution on skin. | 04-24-2014 |
20140113971 | Topical NSAID Compositions Having Sensate Component - Topical pharmaceutical compositions comprising a topically administrable NSAID, a sensate agent and optionally a self-warming system, when administered to a patient in need thereof, provide significant improvements in the rate and extent of skin absorption, as well as impart a sensation of rapid and complete relief from pain. | 04-24-2014 |
20140128472 | TREATMENT AND PREVENTION OF DISEASES RELATED TO OXIDATIVE STRESS - The present invention relates to the field of treatment and prevention of conditions related to oxidative stress and hormone resistance. Preferably, insulin resistance, erythropoietin resistance and acetyl-choline resistance are in the focus. The invention also relates to the field of use of amino acids, in particular p-L-Tyrosine and a precursor thereof as a medicament or composition or formulation in the prevention or treatment of said conditions. | 05-08-2014 |
20140135397 | HALOGENATED PHENOLS FOR DIAGNOSTICS, ANTIOXIDANT PROTECTION AND DRUG DELIVERY - The present invention provides compositions and methods for the targeted delivery, release and/or formation of a drug compound at a target site(s) within the body of an individual, such as a diseased and/or inflamed tissue in the body of the individual. These compositions may comprise a halogenated phenol ring cleavably linked to a core structure of a drug compound. Due to the variety of substituents that may be utilized in forming the different types of linkages, numerous examples of drug compounds linked to a halogenated phenol ring are proposed. The present invention further provides compositions comprising halogenated phenol starting compounds that do not undergo cleavage during a dehalogenation reaction to form a drug compound in a targeted tissue when administered to an individual. Methods of administering these non-cleaving compounds are further provided. | 05-15-2014 |
20140142182 | Aqueous Liquid Composition Containing 2-Amino-3-(4-Bromobenzoyl)Phenylacetic Acid - An aqueous liquid composition comprising: (a) 2-amino-3-(4-bromobenzoyl)phenylacetic acid or its pharmacologically acceptable salt or hydrate; (b) a non-ionic surfactant; and (c) a preservative; wherein at least 90 percent of the original amount of said 2-amino-3-(4-bromobenzoyl)phenylacetic acid or pharmacologically acceptable salt or hydrate remains in the composition after storage at 60° C., for 4 weeks. The composition can satisfy the preservative efficacy of US Pharmacopeia 35 (2012). The composition is useful for the treatment of ocular or nasal inflammation of diverse etiology. | 05-22-2014 |
20140142183 | AQUEOUS LIQUID PREPARATION CONTAINING 2-AMINO-3-(4-BROMOBENZOYL)PHENYLACETIC ACID - An aqueous liquid preparation of the present invention containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid or its pharmacologically acceptable salt or a hydrate thereof, an alkyl aryl polyether alcohol type polymer such as tyloxapol, or a polyethylene glycol fatty acid ester such as polyethylene glycol monostearate is stable. Since even in the case where a preservative is incorporated into said aqueous liquid preparation, the preservative exhibits a sufficient preservative effect for a long time, said aqueous liquid preparation in the form of an eye drop is useful for the treatment of blepharitis, conjunctivitis, scleritis, and postoperative inflammation. Also, the aqueous liquid preparation of the present invention in the form of a nasal drop is useful for the treatment of allergic rhinitis and inflammatory rhinitis (e.g. chronic rhinitis, hypertrophic rhinitis, nasal polyp, etc.). | 05-22-2014 |
20140163105 | TOPICAL PREPARATION FOR PAIN RELIEF - A composition for pain relief including synergistically effective amounts of an amino benzoate local anesthetic, methylsulfonylmethane (MSM), and ethoxydiglycol. A method of treating pain, by applying the composition to skin in an area of pain, and blocking nerve signals. A method of improving range of motion in an individual, by applying the composition to skin, relieving pain, and allowing the individual to have an improved range of motion at an area of pain. | 06-12-2014 |
20140171507 | AMINO ACID DERIVATIVES FOR THE TREATMENT OF NEUROPATHIC PAIN - The invention relates to compounds, to compositions comprising the same and uses thereof for the prevention or treatment of pain, e.g neuropathic pain while having neutral or beneficial effect on metabolic parameters. | 06-19-2014 |
20140179784 | LEVOTHYROXINE FORMULATION WITH CARRAGEENAN - A pharmaceutical composition comprising thyroxine and carrageenan. The pharmaceutical composition has an improved shelf life compared to other pharmaceutical compositions containing thyroxine. In one embodiment, the composition additionally comprises sucrose, microcrystalline cellulose, and mannitol. The pharmaceutical composition may be used for treating thyroid disorders by orally administering the composition to a patient in need thereof. | 06-26-2014 |
20140179785 | SINGLE-DOSE PHARMACEUTICAL PREPARATION OF THYROID HORMONES T3 AND/OR T4 - The present invention relates to a single-dose formulation for oral use of the thyroid hormones triiodothyronine or liothyronine (T3) and tetraiodothyronine or thyroxine (T4) in water-alcohol solution, which is physically and chemically stable, protected against accidental or microbiological contamination, in a container for pharmaceutical use which is squeezable and impermeable to the evaporation of the volatile substances it contains, and the corresponding means for implementing it. | 06-26-2014 |
20140179786 | Treatment of Alzheimer's Disease Using Tolfenamic Acid - A method is disclosed of reducing the level of tau protein in a subject's brain for the treatment of tau tangles. The method includes administrating an effective dose of drug that reduced Sp1 levels to the subject to lower tau mRNA and protein levels, CDK5 mRNA and protein levels, as well phosphorylated tau in the brain. | 06-26-2014 |
20140187635 | DICLOFENAC COMPOSITIONS - The present invention relates a composition comprising Diclofenac and salts thereof wherein Diclofenac or its salts are present in an amount of 25-200 mg. The composition is suitable for the parenteral administration through intramuscular, intravenous route; also for oral, dermal, subcutaneous, cutaneous, nasal, ocular drops, as rectal suppository, vaginal pessaries, intra-articular, and otic delivery. The invention also provides compositions comprising a combination of Diclofenac and other drugs. The invention further provides a method for preparing said composition. | 07-03-2014 |
20140221490 | METHODS OF TREATING PAIN - The presently disclosed subject matter is directed to methods of treating post-operative pain by administering a combination of a lower than minimum approved dose of diclofenac and beta-cyclodextrin. The presently disclosed subject matter is also directed to methods of treating pain in high risk or obese mammals in need of analgesia. | 08-07-2014 |
20140235721 | AQUEOUS LIQUID PREPARATION CONTAINING 2-AMINO-3-(4-BROMOBENZOYL)PHENYLACETIC ACID - An aqueous liquid preparation of the present invention containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid or its pharmacologically acceptable salt or a hydrate thereof, an alkyl aryl polyether alcohol type polymer such as tyloxapol, or a polyethylene glycol fatty acid ester such as polyethylene glycol monostearate is stable. Since even in the case where a preservative is incorporated into said aqueous liquid preparation, the preservative exhibits a sufficient preservative effect for a long time, said aqueous liquid preparation in the form of an eye drop is useful for the treatment of blepharitis, conjunctivitis, scleritis, and postoperative inflammation. Also, the aqueous liquid preparation of the present invention in the form of a nasal drop is useful for the treatment of allergic rhinitis and inflammatory rhinitis (e.g. chronic rhinitis, hypertrophic rhinitis, nasal polyp, etc.). | 08-21-2014 |
20140243413 | AQUEOUS LIQUID PREPARATION CONTAINING 2-AMINO-3-(4-BROMOBENZOYL)PHENYLACETIC ACID - An aqueous liquid preparation of the present invention containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid or its pharmacologically acceptable salt or a hydrate thereof, an alkyl aryl polyether alcohol type polymer such as tyloxapol, or a polyethylene glycol fatty acid ester such as polyethylene glycol monostearate is stable. An embodiment of said liquid preparation does not include any preservative. Said aqueous liquid preparation in the form of an eye drop is useful for the treatment of blepharitis, conjunctivitis, scleritis, and postoperative inflammation. Also, the aqueous liquid preparation of the present invention in the form of a nasal drop is useful for the treatment of allergic rhinitis and inflammatory rhinitis (e.g. chronic rhinitis, hypertrophic rhinitis, nasal polyp, etc.). | 08-28-2014 |
20140275261 | DICLOFENAC PARENTERAL COMPOSITIONS - The present application provides parenteral compositions of diclofenac or its pharmaceutically acceptable salt and methods for making and using such compositions. | 09-18-2014 |
20140288178 | INHIBITION OF c-MYC UBIQUITINATION TO PREVENT CANCER INITIATION AND PROGRESSION - The present invention is directed to methods of inhibiting cancer cell proliferation, differentiation and/or survival. These methods involve the administration of Fbw7 E3 ligase inhibitors to inhibit c-Myc ubiquitination in cancerous cell populations, such as leukemic initiating cell populations, that are responsible for disease initiation and progression. | 09-25-2014 |
20140316007 | THERAPEUTIC COMBINATION OF MEMANTINE AND BACLOFEN AND PHARMACEUTICAL COMPOSITION CONTAINING THEM - The present invention relates to the combination of memantine and baclofen active ingredients, and also to the method for achieving body weight loss and thereby treating obesity and related co-morbidities by co-administration of baclofen and memantine. | 10-23-2014 |
20140323575 | TYROSINE ISOMERS AS THERAPEUTIC AGENTS - The present invention relates to prevention or treatment of diseases related to abnormal cell proliferation, such as cancer, by administering meta- or ortho-tyrosine to a subject in need thereof, for instance a human subject. More specifically, the present invention provides isomers of tyrosine for its use in the prevention or treatment of a disease and in the preparation of pharmaceutical compositions, methods of treating or preventing diseases, such as cancer and cancer metastases, and pharmaceutical compositions containing meta- and/or ortho-tyrosine. | 10-30-2014 |
20140364503 | READY-TO-USE CO-SOLVENTS PHARMACEUTICAL COMPOSITION IN MODIFIED FLEXIBLE PLASTIC CONTAINER - A ready-to-use injectable, co-solvents (ternary mixture) pharmaceutical composition for the treatment of cardiac conditions and diagnosis applications, comprising methyl-3-[4-(2-hydroxy-3-isopropylamino)propoxy]phenylpropionate hydrochloride (Esmolol hydrochloride), a buffering agent, ethanol and propylene glycol which capable of been stored in modified flexible plastic container, heat-sterilized without deformation and/or integrity of the closure system been compromised, as well as method for its manufacture, is disclosed. | 12-11-2014 |
20140371317 | Silicone Resin Emulsions - The present disclosure relates to compositions comprising: i) an aqueous silicone emulsion comprising; A) 0.5 wt % to 95 wt % of a silicone gum, resin, or PSA, B) 0.1 to 90 wt % of an ethylene oxide/propylene oxide block copolymer, and sufficient amount of water to sum all ingredients of the silicone gum emulsion to 100 weight percent, ii) a healthcare active, and iii) an optional enhancer(s). | 12-18-2014 |
20140378546 | METHOD OF TREATING POSTURAL REFLEX ABNORMALITY CAUSED BY PARKINSON'S DISEASE - The present disclosure relates to a more effective therapeutic agent capable of improving and treating the axial symptoms (particularly freezing of gait symptom) of patients with Parkinson's disease. Such symptoms in patients with Parkinson's disease can be improved and treated by using L-threo-3,4-dihydroxy-phenylserine (DOPS) and a COMT inhibitor in combination together, optionally with an L-DOPA preparation as well. As a result, the axial symptoms difficult to improve with conventional L-DOPA preparations can be treated, and a therapeutic agent and a treatment method are provided for the axial symptoms of patients with Parkinson's disease, particularly those suffering from the disease at a moderate level or higher. | 12-25-2014 |
20150011634 | AQUEOUS LIQUID PREPARATION CONTAINING 2-AMINO-3-(4-BROMOBENZOYL)PHENYLACETIC ACID - An aqueous liquid preparation of the present invention containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid or its pharmacologically acceptable salt or a hydrate thereof, an alkyl aryl polyether alcohol type polymer such as tyloxapol, or a polyethylene glycol fatty acid ester such as polyethylene glycol monostearate is stable. Since even in the case where a preservative is incorporated into said aqueous liquid preparation, the preservative exhibits a sufficient preservative effect for a long time, said aqueous liquid preparation in the form of an eye drop is useful for the treatment of blepharitis, conjunctivitis, scleritis, and postoperative inflammation. Also, the aqueous liquid preparation of the present invention in the form of a nasal drop is useful for the treatment of allergic rhinitis and inflammatory rhinitis (e.g. chronic rhinitis, hypertrophic rhinitis, nasal polyp, etc.). | 01-08-2015 |
20150011635 | DICLOFENAC TOPICAL FORMULATION - The present invention provides a gel formulation comprising diclofenac sodium which has superior transdermal flux properties, which may be used for the topical treatment of pain, such as in osteoarthritis. | 01-08-2015 |
20150025148 | ALDITOL FREE, STORAGE STABLE THYROID HORMONE ACTIVE DRUG FORMULATIONS AND METHODS FOR THEIR PRODUCTION - Embodiments of the present invention provide pharmaceutical compositions in unit dosage form that comprise a therapeutically effective amount of levothyroxine sodium; an antioxidant in an amount sufficient to stabilize the levothyroxine sodium against oxidation; an amount of one or more of a monosaccharide, a disaccharide, and an oligosaccharide sufficient to stabilize the levothyroxine sodium; and two or more of a filler, a binder, and a lubricant. Such compositions are free of added alditol and are storage stable | 01-22-2015 |
20150025149 | AQUEOUS LIQUID PREPARATION CONTAINING 2-AMINO-3-(4-BROMOBENZOYL)PHENYLACETIC ACID - An aqueous liquid preparation of the present invention containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid or its pharmacologically acceptable salt or a hydrate thereof, an alkyl aryl polyether alcohol type polymer such as tyloxapol, or a polyethylene glycol fatty acid ester such as polyethylene glycol monostearate is stable. Since even in the case where a preservative is incorporated into said aqueous liquid preparation, the preservative exhibits a sufficient preservative effect for a long time, said aqueous liquid preparation in the form of an eye drop is useful for the treatment of blepharitis, conjunctivitis, scleritis, and postoperative inflammation. Also, the aqueous liquid preparation of the present invention in the form of a nasal drop is useful for the treatment of allergic rhinitis and inflammatory rhinitis (e.g. chronic rhinitis, hypertrophic rhinitis, nasal polyp, etc.). | 01-22-2015 |
20150045436 | Compounds and their Salts Specific to the PPAR Receptors and the EGF Receptors and their Use in the Medical Field - The present invention relates to compounds comprising the general formula (I), in which R | 02-12-2015 |
20150045437 | TRANSDERMAL DELIVERY KITS - Provided are kits containing a base composition and an active pharmaceutical ingredient for transdermal delivery of active pharmaceutical ingredients. Examples of active pharmaceutical ingredients include amitriptyline, baclofen, cyclobenzaprine HCl, ibuprofen, lidocaine HCl, naproxen and tramadol, ketoprofen, diclofenac, phenylbutazone, mefenamic acid, flubiprofen, piroxicam, guaifenasin, prilocaine, bupivicaine, tetracaine, nifedipine, verapamil, orphenadrine, imipramine, ketamine, gabapentin, carbamazepine, menthol, capsaicin, clonidine, dexamethasone, dextromethorphan, testosterone, progesterone, and estrogens. | 02-12-2015 |
20150045438 | AMANTADINE COMPOSITIONS AND METHODS OF USE - Methods of nighttime administration of amantadine to reduce sleep disturbances in patient undergoing treatment with amantadine are described, as well as compositions of extended release amantadine that are suitable for nighttime administration. | 02-12-2015 |
20150045439 | AMANTADINE COMPOSITIONS AND METHODS OF USE - Methods of nighttime administration of amantadine to reduce sleep disturbances in patient undergoing treatment with amantadine are described, as well as compositions of extended release amantadine that are suitable for nighttime administration. | 02-12-2015 |
20150051286 | ANTHRANILIC ACID DERIVATIVES: NOVEL INHIBITORS OF ADVANCED GLYCATION END-PRODUCTS (AGES) FORMATION - Anthranilic acid derivatives are used to inhibit the formation of advanced glycation end products to reduce complications in diabetes. | 02-19-2015 |
20150057355 | AMANTADINE COMPOSITIONS AND METHODS OF USE - Methods of nighttime administration of amantadine to reduce sleep disturbances in patient undergoing treatment with amantadine are described, as well as compositions of extended release amantadine that are suitable for nighttime administration. | 02-26-2015 |
20150073053 | TREATMENT OF DRUG RESISTANT CANCER - The present invention discloses novel agents and methods for diagnosis and treatment of melanoma. Also disclosed are related arrays, kits, and screening methods. | 03-12-2015 |
20150087708 | METHODS OF TREATING FIBROSIS - The present disclosure is directed in part to methods of treating fibrosis, e.g., hepatic fibrosis and/or intestinal fibrosis, comprising administering to a patient in need thereof an effective amount of a disclosed compound. | 03-26-2015 |
20150105466 | INTRATHECAL BACLOFEN PHARMACEUTICAL DOSAGE FORMS WITH FEWER DEGRADATION PRODUCTS - The present invention relates generally to a sterile, particulate-free, stable intrathecal baclofen solution with less than 0.5% of 4-(4-chlorophenyl)-2-pyrrolidone, a degradation product. These solutions are stable under a variety of storage conditions and for extended periods of time. Also disclosed are methods for preparing such compositions. | 04-16-2015 |
20150105467 | FORMULATIONS OF LOW DOSE DICLOFENAC AND BETA-CYCLODEXTRIN - The present invention is directed to a pharmaceutical composition containing a unit dose of a diclofenac compound effective to induce analgesia; and a beta-cyclodextrin compound; wherein the dose of the diclofenac compound is less than 10 mg. The present invention is also directed to methods of treating a subject in need of analgesia with the pharmaceutical compositions of the invention. | 04-16-2015 |
20150126606 | DICLOFENAC TOPICAL FORMULATION - The present invention provides a gel formulation comprising diclofenac sodium which has superior transdermal flux properties, which may be used for the topical treatment of pain, such as in osteoarthritis. | 05-07-2015 |
20150126607 | DICLOFENAC TOPICAL FORMULATION - The present invention provides a gel formulation comprising diclofenac sodium which has superior transdermal flux properties, which may be used for the topical treatment of pain, such as in osteoarthritis. | 05-07-2015 |
20150133557 | ALDITOL FREE AND SACCHARIDE FREE STORAGE-STABLE THYROID HORMONE ACTIVE DRUG FORMULATIONS AND METHODS FOR THEIR PRODUCTION - Embodiments of the present invention provide pharmaceutical compositions in unit dosage form that possess a therapeutically effective amount of a levothyroxine sodium; an antioxidant in an amount sufficient to inhibit oxidation of the levothyroxine sodium in the unit dosage form; an amount of a calcium phosphate sufficient to facilitate a processing of the levothyroxine into the unit dosage form, and two or more excipients selected from the group consisting of a filler, a binder, a glidant, a lubricant, a disintegrant, and a surfactant. In such embodiments, the compositions are free of added alditol, added monosaccharide, added disaccharide, and added oligosaccharide and are storage stable. | 05-14-2015 |
20150141515 | COMPOSITIONS AND METHODS FOR DELIVERY OF NSAID AND ANESTHETIC - The invention relates generally to non-steroidal anti-inflammatory drugs (NSAIDs) and anesthetics, and more particularly, to NSAID and anesthetic compositions, methods of preparing/producing the compositions and methods of delivering, distributing and administering the compositions to patients. | 05-21-2015 |
20150148420 | METHODS FOR TREATING INSOMNIA - Methods for treating insomnia are disclosed. The methods are directed to administering a pharmaceutically effective amount of baclofen to an individual suffering from insomnia. In addition, due to baclofen's positive effects on reducing nighttime reflux events, the present methods are directed to treating insomnia in patients that also suffer from nighttime reflux or gastroesophageal reflux disease (GERD) by administering a pharmaceutically effective amount of baclofen. | 05-28-2015 |
20150306222 | AQUEOUS LIQUID BROMFENAC COMPOSITION HAVING PRESERVATIVE EFFICACY - An aqueous liquid bromfenac composition containing (a) bromfenac or a salt thereof and (b) benzalkonium chloride, characterized by that the composition has preservative efficacy and that the concentration of (b) benzalkonium chloride is higher than 0.0005% and lower than 0.005%. | 10-29-2015 |
20150313998 | DICLOFENAC TOPICAL FORMULATION - The present invention provides a gel formulation comprising diclofenac sodium which has superior transdermal flux properties, which may be used for the topical treatment of pain, such as in osteoarthritis. | 11-05-2015 |
20150320688 | TABLET QUICKLY DISINTEGRATING IN THE ORAL CAVITY AND METHOD FOR PRODUCING THE SAME - The invention relates to a tablet which is rapidly disintegrated in an oral cavity containing an active ingredient at a high content and a production method thereof. That is, the present invention provides a tablet which is rapidly disintegrated in an oral cavity containing an active ingredient in not less than 25% of the total weight, having a disintegration time of within 40 seconds and an absolute hardness of 1.8 N/mm | 11-12-2015 |
20150320707 | TREATMENT OF PAIN WITH TOPICAL DICLOFENAC - The field involves compositions useful for pain relief, including diclofenac solution and gel formulations, in particular methods of use thereof, articles of manufacture and kits that provide novel preclinical, clinical and other information to users. | 11-12-2015 |
20150320709 | METHODS AND COMPOSITIONS FOR FACILITATING WEIGHT LOSS BY ADMINISTRATION OF THYROID HORMONES - The present invention provides methods and compositions for facilitating weight loss in subjects who are undergoing a weight loss regimen by administration of thyroid hormones, for example, T | 11-12-2015 |
20150335546 | NITRONE COMPOUNDS AND THEIR USE IN PERSONAL CARE - Provided are compounds and compositions thereof that are useful as antioxidants in personal care formulations. The compounds are of the formula I: | 11-26-2015 |
20150359740 | COMPOSITION AND METHOD FOR COMPOUNDED THERAPY - A compounded transdermal cream may include gabapentin, diclofenac, cyclobenzaprine, or a combination thereof. The compounded transdermal cream may further include lidocaine in an amount between approximately 0.5% to approximately 5.0% by weight of the compounded transdermal cream and prilocaine in an amount between approximately 0.5% to approximately 5.0% by weight of the compounded transdermal cream. | 12-17-2015 |
20150359766 | METHODS OF TREATING AUTISM WITH mGluR5 ANTAGONISTS - mGluR5 antagonists are used for the treatment of autism. The human treated by the methods of the invention can also have fragile X syndrome, epilepsy and anxiety. | 12-17-2015 |
20160008306 | DICLOFENAC SUBLINGUAL SPRAY | 01-14-2016 |
20160015641 | Levothyroxine Formulations - A levothyroxine composition includes levothyroxine sodium and mannitol. The composition is a lyophilized solid. The composition may include from 100 to 500 micrograms levothyroxine sodium and from 0.1 to 7 milligrams mannitol. | 01-21-2016 |
20160015663 | Methods for Reducing Inter-Patient Variability of Levodopa Plasma Concentrations - The present invention provides methods of reducing the inter-patient variability of levodopa plasma concentrations in a population of Parkinson's disease patients. The methods of the invention comprise pulmonary administration of levodopa at therapeutically effective concentrations such that the inter-patient variability of levodopa plasma concentrations at time periods ranging from about 10 minutes post inhalation to about 60 minutes or more post inhalation have less than a 50% coefficient variation. The methods of the invention are particularly useful for treatment of motor fluctuations which arise as a side effect of L-Dopa therapy. | 01-21-2016 |
20160045605 | DICLOFENAC TOPICAL FORMULATION - The present invention provides a gel formulation comprising diclofenac sodium which has superior transdermal flux properties, which may be used for the topical treatment of pain, such as in osteoarthritis. | 02-18-2016 |
20160051490 | NEUROPROTECTIVE EFFECT OF CAROTENOIDS IN BRAIN - The present invention provides use of composition containing molecular dispersions of carotenoids for the prevention of neurodegenerative disorders which are safe for human consumption and are particularly useful as dietary supplements for nutrition and health promoting benefits. The present invention particularly relates to the use of highly water soluble composition with enhanced bioavailability containing at least 80% by weight of total xanthophylls, out of which the trans-lutein content is 80-95% w/w; (R,R)-zeaxanthin is 14-20% w/w; (R,S)-zeaxanthin is 0.01-1% w/w and traces of other carotenoids derived from the plant extracts/oleoresin containing xanthophylls/xanthophylls esters. The present invention also provides use of the said composition in treatment of neurodegenerative disorders when co-administered along with reduced dose of Levodopa and Carbidopa. | 02-25-2016 |
20160058707 | NOVEL FORMULATION OF DICLOFENAC - The present invention relates to methods for producing particles of diclofenac using dry milling processes as well as compositions comprising diclofenac, medicaments produced using diclofenac in particulate form and/or compositions, and to methods of treatment of an animal, including man, using a therapeutically effective amount of diclofenac administered by way of said medicaments. | 03-03-2016 |
20160058724 | BACLOFEN FORMULATIONS AND METHODS FOR MAKING SAME - Methods for preparing sterilized baclofen solutions include adjusting the pH to below a desired pH, and steam sterilizing the solution with adjusted pH, which results in the solution having the desired pH. Such solutions may also have low concentrations of 4-CPP. Injectable baclofen solutions having greater than 2 mg/mL baclofen include between 5 mM and 25 mM of a phosphate or sulfate species. The solution has an ionic strength equivalent of about 1.5 M NaCl. The present application also provides baclofen formulations for use in treating spasticity, brain injury, cerebral palsy, spinal cord injury, cervical injury, multiple sclerosis, thoracic injury, or withdrawal symptoms. | 03-03-2016 |
20160074351 | DISPENSING SYSTEM - The invention provides systems and methods for controlled dispensing of topical analgesics contained in a metered dispensing system. The systems and method are useful for treating signs and symptoms of osteoarthritis. The method includes depressing a hand pump to dispense a dose of a topical pain reliever in a viscous solution from the hand pump, wherein the hand pump is configured to dispense the dose within a tolerance specified by a corresponding label approved by a government regulatory agency; and spreading the topical solution on skin. | 03-17-2016 |
20160095832 | TOPICAL COMPOSITION FOR PAIN RELIEF - The composition comprises 0.5% to 10% by weight of a neuropathic analgesic; 0.5% to 10% by weight of a muscle relaxant; 0.5% to 20% by weight of an anti-inflammatory analgesic; and 0.5% to 10% by weight of an anesthetic. | 04-07-2016 |
20160136120 | TRANSDERMAL DELIVERY KITS - Provided are kits containing a base composition and an active pharmaceutical ingredient for transdermal delivery of active pharmaceutical ingredients. Examples of active pharmaceutical ingredients include amitriptyline, baclofen, cyclobenzaprine HCl, ibuprofen, lidocaine HCl, naproxen, and tramadol, ketoprofen, diclofenac, phenylbutazone, mefenamic acid, flubiprofen, piroxicam, guaifenasin, prilocaine, bupivicaine, tetracaine, nifedipine, verapamil, orphenadrine, imipramine, ketamine, gabapentin, carbamazepine, menthol, capsaicin, clonidine, dexamethasone, dextromethorphan, testosterone, progesterone, and estrogens. | 05-19-2016 |
20160143855 | STABLE PHARMACEUTICAL COMPOSITIONS OF THYROID HORMONE DRUG - The present invention relates to pharmaceutical compositions comprising a thyroid hormone drug. The invention also relates to processes for the preparation of such compositions. | 05-26-2016 |
20160143869 | STABLE BROMFENAC SOLUTION - The present invention provides a stable, aqueous solution comprising bromfenac or a pharmacologically acceptable salt, polymorph, ester or hydrate thereof and/or pharmaceutically acceptable excipients wherein the invention is preferably devoid of an alkyl aryl polyether alcohol type polymer such as tyloxapol, a polyethylene glycol fatty acid ester such as polyethylene glycol monostearate and BAC. Also the present invention is preferably devoid of antioxidants such as sulfite but not limited to sodium sulfite, potassium sulfite and the like. The present invention also provides for a method for treating ocular inflammation and pain, e.g., after cataract surgery, wherein the method comprises topical application of a formulation according to the present invention to the eye of a patient in need thereof. | 05-26-2016 |
20160151307 | AMANTADINE COMPOSITIONS AND METHODS OF USE | 06-02-2016 |
20160158178 | DOSAGE FORMS AND THERAPEUTIC USES L-4-CHLOROKYNURENINE - Compositions of L-4-chlorokynurenine are provided, as are methods for the treatment of neurological dysfunction. | 06-09-2016 |
20160166523 | TOPICAL PHARMACEUTICAL GEL COMPOSITION OF DICLOFENAC SODIUM | 06-16-2016 |
20160166524 | TOPICAL PHARMACEUTICAL GEL COMPOSITION OF DICLOFENAC SODIUM | 06-16-2016 |
20160374970 | PHARMACEUTICAL COMPOSITION - A pharmaceutical composition for application in human and animals, with at least one systemically and/or locally acting, topically applicable active ingredient and with at least one phospholipid, improving the transport of the active ingredient trough the cell membrane and containing a concentration of at least 60% by weight phosphatidylcholine, referring to the phospholipid, is described. The composition shows such a liquid consistency, that it is able to be sprayed as droplets or as a foam, whereas in the composition such a phospholipid is included, that additionally contains oil in a concentration of maximum 7.5% by weight besides the at least 60% by weight phosphatidylcholine. | 12-29-2016 |